Barbato, Anna
Piscopo, Fabiola
Salati, Massimiliano
Pollastro, Carla
Evangelista, Lorenzo
Ferrante, Luigi
Limongello, Davide
Brillante, Simona
Iuliano, Antonella
Reggiani-Bonetti, Luca
Salatiello, Maria
Iaccarino, Antonino
Pisapia, Pasquale
Malapelle, Umberto
Troncone, Giancarlo
Indrieri, Alessia
Dominici, Massimo
Franco, Brunella
Carotenuto, Pietro
Funding for this research was provided by:
Ministero dell'Istruzione, dell'Universita' (PRIN2020 - 2020XBCMHJ, PRIN2020 - 2020XBCMHJ)
Ministero dell’Istruzione, dell’Università e della Ricerca (PRIN2022 - 20227RH9M4, PRIN2022 - 20227RH9M4, PRIN2022 - 20227RH9M4)
Fondazione AIRC per la ricerca sul cancro ETS (IG26414/2021, IG26414/2021)
H2020 Marie Skłodowska-Curie Actions (800924)
Regione Campania (Genomica e Terapia)
Università degli Studi di Napoli Federico II
Article History
Received: 25 January 2024
Accepted: 14 March 2024
First Online: 10 April 2024
Declarations
:
: (AI, BF filed and licensed patent applications on “miR-181 inhibitors and uses thereof” (WO2019202162A1). UM has received personal fees (as consultant and/or speaker bureau) from Boehringer Ingelheim, Roche, MSD, Amgen, Thermo Fisher Scientific, Eli Lilly, Diaceutics, GSK, Merck and AstraZeneca, Janssen, Diatech, Novartis and Hedera unrelated to the current work. GT reports personal fees (as speaker bureau or advisor) from Roche, MSD, Pfizer, Boehringer Ingelheim, Eli Lilly, BMS, GSK, Menarini, AstraZeneca, Amgen and Bayer, unrelated to the current work. The other Authors have nothing to disclose.
: The human BTC tissues were collected under approval of the Ethical Committee for Clinical Research at Azienda Ospedaliera Universitaria, Modena, Italy (ID 465/2018/SPER/AOUMO). The study protocols conformed to the ethical guidelines of the 1975 Declaration of Helsinki, as per ethical approval given by the institutional review board.